For instance, Nrf2 activation driven by KEAP1 mutations accelerates lung cancer progression [48] while its inhibition can sensitize colorectal cancer cells to oxaliplatin-induced ferroptosis [49]. This evidence concerns the gene KEAP1 and lung carcinoma.